Hair Relaxer Uterine Cancer Lawsuits

Women who regularly used chemical hair relaxers and were diagnosed with uterine cancer may be entitled to significant compensation.

Filing Deadline

Filing Now

Settlement Info

10,168 lawsuits pending as of May 2025. First trials scheduled for 2027.

Overview

Recent studies have linked chemical hair relaxers to an increased risk of uterine cancer, endometrial cancer, and other hormone-related cancers in women who used these products regularly.

Key Facts

Active Cases: 10,168 lawsuits in MDL as of May 2025
Defendants: L'Oréal, Revlon, and other manufacturers
First Trials: Scheduled for 2027
Primary Condition: Uterine/endometrial cancer

Who Qualifies?

You may be eligible if you:

Used chemical hair relaxers regularly (4+ times per year)
Were diagnosed with uterine or endometrial cancer
Used products for an extended period
Are between ages 35-70

Scientific Evidence

NIH studies show increased cancer risk with regular use
Chemical ingredients include formaldehyde and other carcinogens
Higher risk for women who started using products at young age

Eligible Diagnoses

Uterine cancer
Endometrial cancer
Ovarian cancer
Breast cancer (in some cases)

Settlement Potential

While trials are scheduled for 2027, early settlements may be possible. The MDL continues to grow rapidly, indicating strong evidence against manufacturers.